MGB Biopharma is a clinical-stage company developing a novel class of anti-infectives, headquartered in Glasgow, Scotland. Its lead candidate, MGB-BP-3, is being developed as an oral formulation for the treatment of Clostridium difficile-associated diarrhoea (CDAD). The company also maintains a pipeline of early preclinical compounds targeting Gram-positive, Gram-negative and antifungal pathogens. MGB Biopharma acquired rights to the proprietary minor groove binder (MGB) platform from the University of Strathclyde with exclusive worldwide licensing rights for all anti-infective fields, including Gram-negative bacteria. The company was founded in 2010 and recently completed a funding round of undisclosed amount. It plans to use the funds to complete activities around its ongoing Phase IIa trial of MGB-BP-3, prepare for subsequent development stages, and progress other programmes through to H2 2020. MGB Biopharma develops MGB-BP-3, an antibacterial active against a broad range of multi-resistant and susceptible Gram-positive pathogens. The company has an oral formulation of MGB-BP-3 for treatment of Clostridium difficile-associated disease (CDAD) and completed a Phase I study. It is preparing a Phase II study designed to investigate safety and efficacy in patients with CDAD, including the virulent ribotype B1/NAP1/027. An intravenous formulation targeting systemic hospital-acquired Gram-positive infections is in late-stage preclinical development. A topical formulation for serious skin infections has shown encouraging efficacy data. The company will use the recently raised funds to advance MGB-BP-3 toward Phase II. MGB Biopharma is developing a truly novel class of anti-infectives based on minor groove binder (MGB) technology; its lead candidate MGB-BP-3 targets a broad range of multi-resistant Gram-positive pathogens including Clostridium difficile and Staphylococcus species. The company has an oral formulation ready to enter the clinic for C. difficile and an intravenous formulation in late-stage preclinical development for systemic hospital-acquired Gram-positive infections. An oral Phase I trial is planned as a single-centre, double-blind, placebo-controlled study enrolling ~40 healthy subjects to assess safety, tolerability and effects on gut flora, expected to start in the first half of 2015. The IV formulation is being advanced in parallel and the company expects to be IND-ready by the end of next year. MGB Biopharma holds an exclusive worldwide licence to the University of Strathclyde's MGB patents (excluding anticancer) and intends to work with partners to capitalise on its platform. The company was founded in 2010 and is headquartered in Glasgow, Scotland. It has secured funding this year to advance clinical development.

Total raised

$8M

Funding rounds

4

Latest round

Equity

Latest activity

Apr 2017